STAT Plus: Bluebird’s gene therapy for a rare blood disease will cost $1.8 million. Cue the pricing debate
Bluebird Bio (BLUE) won’t be selling the world’s most expensive drug. The second priciest? Yup.
Zynteglo, the one-and-done gene therapy for beta thalassemia newly approved in Europe, will carry a price tag of $1.8 million, Bluebird announced Friday. Only Zolgensma, the Novartis gene therapy for spinal muscular atrophy, is priced higher, at $2.1 million.
Continue to STAT Plus to read the full story…
